Replimune Group (NASDAQ:REPL) Trading 5.2% Higher – Should You Buy?

Replimune Group, Inc. (NASDAQ:REPL)’s share price traded up 5.2% during mid-day trading on Tuesday . The stock traded as high as $15.24 and last traded at $15.3970. Approximately 473,161 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 4,979,744 shares. The stock had previously closed at $14.63.

Analyst Ratings Changes

REPL has been the topic of several research analyst reports. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price on the stock in a research report on Tuesday, June 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $11.86.

Replimune Group Stock Performance

The stock has a market cap of $1.39 billion, a PE ratio of -4.70 and a beta of 0.88. The firm’s 50-day moving average is $11.02 and its 200 day moving average is $7.95. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.79 and a current ratio of 5.23.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). As a group, research analysts anticipate that Replimune Group, Inc. will post -2.78 EPS for the current year.

Insider Buying and Selling at Replimune Group

In related news, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the sale, the chief executive officer owned 708,151 shares in the company, valued at $9,184,718.47. This trade represents a 5.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 91,124 shares of company stock valued at $1,149,244. Insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several institutional investors have recently modified their holdings of REPL. ProShare Advisors LLC increased its stake in Replimune Group by 10.3% in the 4th quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock valued at $157,000 after purchasing an additional 1,505 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Replimune Group by 4.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock worth $159,000 after buying an additional 1,712 shares in the last quarter. Ballentine Partners LLC grew its stake in Replimune Group by 7.8% in the 4th quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock valued at $230,000 after acquiring an additional 1,721 shares during the last quarter. BNP Paribas Financial Markets raised its position in Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after acquiring an additional 1,879 shares during the last quarter. Finally, Walleye Capital LLC grew its position in shares of Replimune Group by 3.2% in the first quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock valued at $548,000 after purchasing an additional 2,192 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.